pg_0001

Medical data is for informational purposes only. You should always consult your family physician, or one of our referral physicians prior to treatment.

History of The Roger Wyburn-Mason

and Jack M. Blount Foundation for

Eradication of Rheumatoid Disease

(AKA The Arthritis Trust of America or

The Rheumatoid Disease Foundation)

by Perry A. Chapdelaine, Sr.

for the Eradication of Rheumatoid Disease

AKA The Arthritis Trust of America

7376 Walker Road, Fairview, Tn 37062

Permission to publish granted to Townsend Letter for Doctors, & Patients, 911

Tyler St., Port Townsend, WA 98368-6541, January 1996, p. 76.

Introduction

Our research started before the Roger Wyburn-Mason and Jack

M. Blount Foundation for Eradication of Rheumatoid Disease was

chartered in the State of Tennessee in 1982.

Professor Roger Wyburn-Mason, M.D., Ph.D. -- author of

several important medical textbooks and a renown specialist in nerve

diseases, honored by having two nerve diseases named after him

during his lifetime -- along with Vice Admiral Stamm, a world-class

protozoologist -- came to the conclusion from their experimental

work that a common Limax amoeba was responsible for about 100

differently named collagen tissue diseases, including Rheumatoid

Arthritis, Scleroderma, Psoriasis, and many other named diseases.

All of these we now call "Rheumatoid Diseases."

Wyburn-Mason and Stamm were probably wrong when iden-

tifying the particular amoeba, Limax, for reasons our later research

uncovered, but the treatment protocol developed from Wyburn-

Mason's hypothesis -- that an organism infecting all systems in the

human body for a person who has a genetic susceptibility for that

organism, causes collagen tissue diseases -- serendipitously deter-

mined the very first medical treatment regimen to consistently and

favorably affect the progress of Rheumatoid Diseases. (See "The

Roger Wyburn-Mason M.D., Ph.D. Treatment for Rheumatoid

Disease," http://www.arthritistrust.org.)

Thomas McPherson Brown, M.D., of course, is owed a great

deal for his research in uncovering the probable role of mycoplasm

in Rheumatoid Disease, and also in developing a successful treat-

ment.

Fom the 1970's onward Professor Roger Wyburn-Mason

experimented with different chemicals that would cure Rheumatoid

Arthritis and related collagen tissue diseases. He developed the

medical use of copper solutions, bile, and other drugs that were not

easy to take, being somewhat toxic, but did have an effect on the

disease; and he finally settled on the use of clotrimazole, tinidazole,

ornidizole, nimorazole, allopurinol, rifampicin, potassium para amino

benzoate and furazolidone.

Professor Roger Wyburn-Mason's research, summarized in

1976-1977, was originally published under the title of The Causation

of Rheumatoid Disease and Many Human Cancers in March 1978

in an expensive, limited hardcover edition, in Japan, and then

summarized in a Precis and Addenda titled the same name as his book

by this foundation in 1983. Both publications are available through

the Rheumatoid Disease Foundation, at http://www.arthritistrust.org.

Robert Bingham, M.D. and

Jack M. Blount, M.D.

Robert Bingham, M.D., an orthopedic surgeon from California,

who had devoted his life to the problems of crippled children, and

later crippled adults, visited Professor Roger Wyburn-Mason in

England, and thereafter tried Wyburn-Mason's treatment with a

great deal of clinical success. He wrote up Wyburn-Mason's hypoth-

esis in Orthopedic Review and Modern Medicine, an article that was

subsequently read by Jack M. Blount, M.D., a Philadelphia, MS

physician who had had crippling Rheumatoid Arthritis all of his adult

life.

New Discoveries

Dr. Blount was bed-ridden, drug- and alcohol-ridden, and no

longer practicing medicine because of the scourges of Rheumatoid

Arthritis.

On reading Dr. Bingham's article, Dr. Blount tried to locate

some of the recommended drugs -- especially Clotrimazole -- but no

drug company would sell them to him in the United States at that time.

Jack Blount, therefore, on reading through the chemical structure of

many different drugs, discovered that Metronidazole was related to

Wyburn-Mason's Clotrimazole, Ornidazole, Nimorazole and

Tinidazole, a class of compounds called the 5-nitroimidazoles.

Dr. Blount got himself and some older patients well on using

Metronidazole, and thereafter reopened his medical clinic, where he

became known throughout the United States for treating and bringing

great relief -- often permanent relief -- to more than 17,000 patients,

including the Executive Director/Secretary of this Foundation. (See

"Rheumatoid Arthritis: Two Case Histories," http://

www.arthritistrust.org.)

Later Robert Bingham, M.D., through his clinical work, added

diiodohydroxyquinon to the list of possibly effective medicines,

Seldon Nelson, D.O. developed and was able to utilize resin-

coated copper ions, which was also added to our recommended

treatment protocol. (See "The Use of Ionic Copper in the Treatment

of Arthritis," http://www.arthritistrust.org.)

Amoebic Research

The Rheumatoid Disease Foundation/AKA The Arthritis Trust

of America was founded by Branch Own Adkerson, M.A.,

Frederick H. Binford, M.A., Robert Bingham, M.D., Jack M.

Blount, M.D. , Milas Brandon, M.D., Warren B. Causey, Perry A.

Chapdelaine, Sr., M.A., E. Harrison Clark, Ph.D., Terry Crommelin,

George Hay, H.P.A., Robert Kemp, Gus J. Prosch, Jr., M.D., Dr.

Paul Pybus (South Africa: a surgeon and former student of Roger

Wyburn-Mason's), Carl J. Reich, M.D., research pharmacologist

John R.A. Simoons, Ph.D., Don Vansant, Eugene S. Wolcott, M.D.,

and Roger Wyburn-Mason, M.D., Ph.D.

As the treatment for various forms of collagen tissue diseases

developed by Roger Wyburn-Mason worked in a high percentage

of cases -- as high as 80% according to the records of some doctors,

providing the patient had not already had their immunological

system ruined by traditional treatments, in which case effectiveness

dropped to about 50% -- this Foundation and its medical advisory

board felt that more should be learned about amoebae. Toward that

end, Tony Chapdelaine, B.A. (now an M.D., M.S.P.H.) volunteered

to work without charge for one year with one of the world's leading

specialists in certain types of amoebae, Robert Neff, Ph.D. of

Vanderbilt University, TN.

They were able to show the effect of different chemical

environments, particularly the effect of our recommended treatment

drugs, on amoebae in vitro (in the test tube).

When Tony Chapdelaine entered medical school, Dr. Neff

assigned a graduate student to finish the project, and Dr. Neff's final